Abstract: A compound selected from those of formula (I): ##STR1## wherein: R.sub.1 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino,R.sub.2 represents optionally substituted aryl or heteroaryl,R.sub.3 represents hydrogen, halogen, alkyl, nitro, hydroxy, alkoxy, trihaloalkyl, trihaloalkoxy or optionally substituted amino,their isomers and addition pharmaceutically-acceptable acid or base salts thereof and medicinal products containing the same are useful in the treatment of cancer.

Abstract: The present invention relates to compounds of formula (I): ##STR1## wherein A, x, y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description. The compounds are useful for treating diseases requiring a selective serotonin reuptake site and 5-HT.sub.2c or 5-HT.sub.3 ligand.

Abstract: The present invention relates to a compound selected from these of formula (I): ##STR1## in which A and R.sub.1 are as defined in the description, and medicinal product containing the same which is useful for treating a disorder linked to the 5-HT.sub.3 receptors.

Abstract: Compounds of the general formula (I): ##STR1## where A, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are defined in the description.Medicinal products.

Abstract: The invention relates to compounds of general formula I: ##STR1## in which: R.sub.1 represents a radical of general formula (Z.sub.0), (Z.sub.1), (Z.sub.2), (Z.sub.3) or (Z.sub.4) ##STR2## R.sub.2 represents a methylene radical, a hydroxymethylene radical, a carbonyl radical or a radical of general formula (Y.sub.1), (Y.sub.2), (Y.sub.3) or (Y.sub.4): ##STR3## or, with R.sub.12 and the nitrogen atom to which they are attached, forms a radical of general formula (W): ##STR4## R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11, R.sub.12 and n being as defined in the description, medicinal products containing the same and a method-of-treating metabolic ailments therewith.

Abstract: The invention relates to pyrrolo [1,2-a] thieno [3,2-f][1,4]diazepine compounds of the formula (I) ##STR1## in which: R.sub.1 is hydrogen; alkyl optionally substituted with alkoxy, hydroxy, cycloalkyl, or phenyl; or alkyl- or arylsulfonyl; R.sub.2 is hydrogen, phenyl, or phenylalkyl; alkyl optionally substituted with hydroxyl, alkoxy, oxo, cycloalkyl or phenyl; or optionally substituted amino; R.sub.3 represents hydrogen or alkyl, and R.sub.4 and R.sub.5 independently represent: hydrogen, alkyl optionally substituted with alkoxy, cycloalkyl, or phenyl; or phenyl; their isomers, diastereoisomers and enantiomers as well as their addition salts with pharmaceutically-acceptable acids. The compounds are useful for treating cerebral ischemia, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, and hyperglycemia and are obtained in a few steps from the corresponding substituted 2-(1-pyrrolyl)thiophenes ##STR2## Y=--CHO or H; X= CN, CONH.sub.2, CH.sub.2 NHCOR.sub.2, or CH.sub.2 NH.sub.2.

Abstract: Novel 4H-pyrrolo[1,2-a]thieno[2,3-f][1,4]diazepine which are usable as a medicinal product and correspond to the general formula (I): ##STR1## in which: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the same meaning as given in the specification.These compounds, as well as their physiologically tolerable salts, may be used in therapy, in particular in the treatment of disorders linked to hypoxemia and to certain metabolic disorders.